ARTICLE | Clinical News
Xoma and Genentech start anti-CD11 trials
March 30, 2000 8:00 AM UTC
XOMA and DNA began a Phase I/II trial of anti-CD11 humanized monoclonal antibody, to selectively inhibit T cells associated with kidney rejection following transplant. The antibody started Phase III t...